Skip to main navigation Skip to search Skip to main content

Risks of dementia and stroke in patients with hypertension using telmisartan or other renin‐angiotensin system inhibitors

  • Chang Gung Memorial Hospital
  • Chang Gung University
  • National Taiwan University
  • New Taipei Municipal Tucheng Hospital

Research output: Contribution to journal › Journal Article › peer-review

4 Scopus citations

Abstract

INTRODUCTION: The aim of this study was to investigate the cognitive and cerebrovascular outcomes of patients with hypertension (HTN) receiving various renin-angiotensin system (RAS) inhibitors. METHODS: We further categorized 39,665 patients with HTN receiving long-term RAS inhibitor therapy into (1) telmisartan, (2) non-telmisartan angiotensin receptor blocker (NT-ARB), and (3) angiotensin-converting enzyme inhibitor groups. The main outcomes were a diagnosis of all dementias and the occurrence of all strokes during follow-up. RESULTS: The telmisartan group had the lowest risk of all dementias (telmisartan vs NT-ARB: hazard ratio [HR]: 0.78; 95% confidence interval [CI]: 0.60 to 1.01; telmisartan vs angiotensin-converting enzyme inhibitor: HR: 0.67; 95% CI: 0.48 to 0.94). The telmisartan group also had a lower risk of all strokes when compared to NT-ARB (HR: 0.78; 95% CI: 0.61 to 0.99) in the time-dependent cohort. DISCUSSION: Use of telmisartan may be associated with marginally lower risks of all dementias and strokes compared to other RAS inhibitors in patients with HTN. Highlights: Whether telmisartan is associated with a reduced risk of dementia compared to other RAS inhibitors in patients with HTN and varying blood sugar levels remains unclear. Our cohort study aimed to investigate the long-term cognitive and cerebrovascular outcomes of hypertensive patients receiving telmisartan compared to those receiving other RAS inhibitors. Eligible individuals were categorized into three groups. Use of telmisartan may be associated with marginally lower risks of all dementia and stroke compared with other RAS inhibitors in patients with HTN.

Original languageEnglish
Article numbere71153
Pages (from-to)e71153
JournalAlzheimer's and Dementia
Volume22
Issue number2
DOIs
StatePublished - 02 2026

Bibliographical note

© 2026 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • angiotensin converting enzyme
  • angiotensin receptor blocker
  • dementia
  • hypertension
  • stroke
  • telmisartan
  • Antihypertensive Agents/therapeutic use
  • Telmisartan/therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors/therapeutic use
  • Humans
  • Middle Aged
  • Risk Factors
  • Male
  • Renin-Angiotensin System/drug effects
  • Dementia/epidemiology
  • Aged, 80 and over
  • Stroke/epidemiology
  • Female
  • Aged
  • Angiotensin Receptor Antagonists/therapeutic use
  • Hypertension/drug therapy

Fingerprint

Dive into the research topics of 'Risks of dementia and stroke in patients with hypertension using telmisartan or other renin‐angiotensin system inhibitors'. Together they form a unique fingerprint.

Cite this